Proton therapy for children with renal tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This pilot study evaluates the use of pencil beam scanning proton therapy in patients with renal tumors, including Wilms tumor and clear cell sarcoma of the kidney. The approach aims to minimize acute gastrointestinal toxicity associated with radiation therapy while maintaining effective treatment. Patients will undergo assessments of health-related quality of life and laboratory evaluations to measure toxicity levels. The study also compares the radiation doses to organs at risk using this advanced proton therapy technique versus traditional photon radiation.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Less than 30 years of age
* Diagnosis

  a. Any patient with Wilms tumor or clear cell sarcoma of the kidney who would require radiation therapy as standard of care including
  1. Any patient with favorable histology (FH), stage III disease
  2. Any patient with focal or diffuse anaplasia
  3. Any patient with CCSK
* The patient is a candidate for external beam radiotherapy based on standard of care for treatment of Wilms tumor or CCSK

Exclusion Criteria:

* Prior radiotherapy to the region of the study cancer
* Chemotherapy administered for diagnosis of Wilms tumor or CCSK
* Pregnant or breastfeeding

Where it's running

• Children's Hospital of Philadelphia
  Philadelphia, Pennsylvania, United States Recruiting

Study contacts

• Principal investigator: Christine Hill-Kayser, MD — Children's Hospital of Philadelphia
• Study coordinator: Christine Hill-Kayser, MD
• Email: hill@uphs.upenn.edu
• Phone: 215-590-2810

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• MRI-based AI to classify and grade renal tumors

  This study tests AI methods on MRI data from adults with kidney tumors to see if they can identify tumor type and grade before surgery.

  Recruiting Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing · NCT07743749

• Becotatug Vedotin for EGFR-positive relapsed, refractory, or metastatic pediatric solid tumors

  This trial will test Becotatug Vedotin, an EGFR-targeted antibody-drug conjugate, to see if it is safe and helps children aged 2–18 with EGFR-positive relapsed, refractory, or metastatic solid tumors.

  Recruiting Phase 1 Sun Yat-sen University · Guangzhou, Guangdong · NCT07584499

• Personalized B7-H3 CAR T cells combined with PRAME antigen-specific T cells for relapsed embryonal tumors

  This trial tests a combined personalized B7-H3 CAR T cell and PRAME-specific T cell infusion after lymphodepleting chemotherapy in children and young adults with relapsed or refractory embryonal tumors.

  Recruiting Phase 1 Children's National Research Institute · Washington D.C., District of Columbia and 1 other locations · NCT07172958

• GPC3-targeted CAR T cells armored with IL-15 and IL-21 for pediatric non‑CNS solid tumors

  This treatment will try personalized CAR T cells that target GPC3 and are engineered to make IL‑15 and IL‑21 in children and young adults with relapsed or refractory non‑CNS solid tumors that express GPC3.

  Recruiting Phase 1 Seattle Children's Hospital · Seattle, Washington · NCT07148050

• Alpha/beta T‑Cell and B‑Cell Depletion plus Zoledronic Acid for Pediatric and Young Adult Solid Tumors

  This study will try removing alpha/beta T cells and B cells from donor stem cell grafts and giving zoledronic acid to see if it helps children and young adults (6 months to 25 years) with relapsed or high‑risk solid tumors tolerate allogeneic transplant and reduce relapse.

  Recruiting Phase 1/2 University of Florida · Gainesville, Florida · NCT06625190

• Comparing robot-assisted kidney surgery in different positions

  This study is testing if having kidney surgery with a robot while lying face down is better for recovery and results compared to the usual side position for patients with kidney tumors.

  Recruiting The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT06572501

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.